Lexicon Pharmaceuticals Stock Performance
| LXRX Stock | USD 0.80 0.02 2.44% |
The company secures a Beta (Market Risk) of 1.15, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Lexicon Pharmaceuticals will likely underperform. At this point, Lexicon Pharmaceuticals has a negative expected return of -0.87%. Please make sure to verify Lexicon Pharmaceuticals' accumulation distribution, as well as the relationship between the day median price and price action indicator , to decide if Lexicon Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Lexicon Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:7 | Last Split Date 2015-05-21 |
1 | Acquisition by Wade Jeffrey L of 307000 shares of Lexicon Pharmaceuticals at 1.67 subject to Rule 16b-3 | 09/17/2024 |
2 | Insider Trading | 10/02/2024 |
3 | Lexicon diabetes drug sotagliflozin fails to win support of FDA AdComm | 10/31/2024 |
4 | Lexicon Pharmaceuticals Q3 2024 Earnings Preview | 11/11/2024 |
5 | Lexicon Pharmaceuticals GAAP EPS of -0.18 misses by 0.01, revenue of 1.75M misses by 1.18M | 11/12/2024 |
6 | FMR LLCs Strategic Acquisition of Lexicon Pharmaceuticals Shares | 11/13/2024 |
7 | Acquisition by Amouyal Philippe of 8032 shares of Lexicon Pharmaceuticals subject to Rule 16b-3 | 11/15/2024 |
8 | Lexicon Appoints Ivan H. Cheung to Board of Directors | 11/20/2024 |
9 | Lexicon to disband sales team, lay off 60 percent of staff | 11/22/2024 |
10 | Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic ... | 11/26/2024 |
| Begin Period Cash Flow | 46.3 M | |
| Free Cash Flow | -162.4 M |
Lexicon |
Lexicon Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 161.00 in Lexicon Pharmaceuticals on September 2, 2024 and sell it today you would lose (81.00) from holding Lexicon Pharmaceuticals or give up 50.31% of portfolio value over 90 days. Lexicon Pharmaceuticals is currently does not generate positive expected returns and assumes 6.1235% risk (volatility on return distribution) over the 90 days horizon. In different words, 54% of stocks are less volatile than Lexicon, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lexicon Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lexicon Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lexicon Pharmaceuticals, and traders can use it to determine the average amount a Lexicon Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1414
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LXRX |
Estimated Market Risk
| 6.12 actual daily | 54 54% of assets are less volatile |
Expected Return
| -0.87 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Lexicon Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lexicon Pharmaceuticals by adding Lexicon Pharmaceuticals to a well-diversified portfolio.
Lexicon Pharmaceuticals Fundamentals Growth
Lexicon Stock prices reflect investors' perceptions of the future prospects and financial health of Lexicon Pharmaceuticals, and Lexicon Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lexicon Stock performance.
| Return On Equity | -1.36 | ||||
| Return On Asset | -0.44 | ||||
| Operating Margin | (36.40) % | ||||
| Current Valuation | 133.36 M | ||||
| Shares Outstanding | 361.49 M | ||||
| Price To Earning | 21.02 X | ||||
| Price To Book | 1.63 X | ||||
| Price To Sales | 55.64 X | ||||
| Revenue | 1.2 M | ||||
| Gross Profit | (52.68 M) | ||||
| EBITDA | (163.46 M) | ||||
| Net Income | (177.12 M) | ||||
| Cash And Equivalents | 61.97 M | ||||
| Cash Per Share | 0.34 X | ||||
| Total Debt | 106.06 M | ||||
| Debt To Equity | 0.36 % | ||||
| Current Ratio | 3.85 X | ||||
| Book Value Per Share | 0.49 X | ||||
| Cash Flow From Operations | (161.9 M) | ||||
| Earnings Per Share | (0.74) X | ||||
| Market Capitalization | 290.97 M | ||||
| Total Asset | 229.43 M | ||||
| Retained Earnings | (1.77 B) | ||||
| Working Capital | 145 M | ||||
| Current Asset | 171.5 M | ||||
| Current Liabilities | 31.77 M | ||||
About Lexicon Pharmaceuticals Performance
Evaluating Lexicon Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Lexicon Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Lexicon Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.5 K | 1.5 K | |
| Return On Tangible Assets | (0.96) | (0.91) | |
| Return On Capital Employed | (0.87) | (0.82) | |
| Return On Assets | (0.77) | (0.73) | |
| Return On Equity | (1.90) | (1.81) |
Things to note about Lexicon Pharmaceuticals performance evaluation
Checking the ongoing alerts about Lexicon Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lexicon Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lexicon Pharmaceuticals generated a negative expected return over the last 90 days | |
| Lexicon Pharmaceuticals has high historical volatility and very poor performance | |
| Lexicon Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Lexicon Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.2 M. Net Loss for the year was (177.12 M) with loss before overhead, payroll, taxes, and interest of (52.68 M). | |
| Lexicon Pharmaceuticals currently holds about 61.97 M in cash with (161.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.34. | |
| Over 82.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic ... |
- Analyzing Lexicon Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lexicon Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Lexicon Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lexicon Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lexicon Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lexicon Pharmaceuticals' stock. These opinions can provide insight into Lexicon Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Lexicon Stock Analysis
When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.